Table 2.
Efficacy of doxycycline with or without quinine for treatment of P. falciparum malaria
| Country (population) | Study type | Sample size/doxycycline dose | Duration of treatment | Cure rate (95% CI) |
|---|---|---|---|---|
| United States (mixture of immune and non-immune)5 | Challenge, open-label | P. vivax: | 4 days | 0 |
| 1/100 mg twice a day | 5 days | 0 | ||
| 7 days | 0 | |||
| 1/100 mg twice a day | 100% | |||
| P. falciparum: | ||||
| 4/100 mg twice a day | ||||
| 9/100 mg twice a day | ||||
| West Malaysia (varied, children aged 2 months–8 years)27 | Challenge, open-label | 9/4 mg/kg daily | 4 days | 44.4% |
| 26/4 mg/kg daily | 7 days | 84.6% | ||
| Irian Jaya, Indonesia (non-immune)26 | Randomized, open-label, comparator = CQ (N = 30) and doxycycline + CQ (N = 39) | 20/100 mg twice a day | 7 days | P. falciparum: 64.7% (42.0–87.4%) |
| P. vivax: 33.3% (6.6–59.5%) | ||||
| Brazil (semi-immune)28 | Randomized, open-label, comparator = AL (N = 28) | 31/100 mg twice a day + 500 mg quinine every 8 hours | 5 days doxycycline | 100% |
| 3 days quinine | ||||
| Pakistan (unknown immune status)29 | Challenge, open-label | 100/100 mg twice a day + 10mg/kg quinine every 8 hours | 7 days doxycycline | 100% |
| 3 days |